Welcome to our dedicated page for BeOne Medicines Ltd. SEC filings (Ticker: ONC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BeOne Medicines Ltd. (ONC) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8‑K and other documents filed with the Securities and Exchange Commission. BeOne is a Switzerland‑domiciled global oncology company whose American Depositary Shares are registered with the SEC, while its ordinary shares trade on the Hong Kong Stock Exchange and it also reports to the STAR Market in Shanghai.
Through its filings, BeOne reports on financial results, material agreements and corporate events. Recent Forms 8‑K referenced in the input include announcements of quarterly financial results, describing revenue growth driven primarily by BRUKINSA product sales and contributions from TEVIMBRA and in‑licensed products. Other 8‑K filings detail a royalty purchase agreement with Royalty Pharma tied to royalty rights on IMDELLTRA (tarlatamab) ex‑China net revenue, as well as the creation of related financial obligations and escrow arrangements.
Additional 8‑K reports cover topics such as the termination of a prior credit facility after arranging new financing, and the appointment and compensation terms of senior research and development leadership. The company also furnishes information about its interim reports filed with the STAR Market, including financial data prepared under China Accounting Standards and summaries of differences from U.S. GAAP.
On Stock Titan, users can review these ONC filings alongside AI‑generated summaries that explain the main points of each document in plain language. This includes highlighting key items in earnings‑related filings, summarizing the structure and implications of material agreements, and pointing out governance or leadership changes disclosed under Item 5.02 of Form 8‑K. Investors can also use the filings page to monitor how BeOne describes its oncology portfolio, collaborations and financial position over time, and to cross‑reference U.S. disclosures with the company’s press releases and non‑U.S. reporting.
Real‑time updates from EDGAR, combined with AI‑assisted overviews, help readers navigate lengthy filings and focus on sections most relevant to their interests, whether they are following BeOne’s hematology and solid tumor programs, its financing arrangements or its multi‑exchange reporting obligations.
BeOne Medicines Ltd. director Alessandro Riva reported a small tax‑related share sale. On 2026-05-22, he sold 212 American Depositary Shares of BeOne Medicines in an open-market transaction at an average price of $309.5142 per ADS. A footnote explains the sale was mandated under a tax withholding provision tied to the vesting of a restricted share unit award, meaning it was executed to cover tax obligations rather than as a discretionary portfolio move. Each American Depositary Share represents 13 Ordinary Shares. After these transactions, a holding entry shows Riva with 54,184 Ordinary Shares held directly.
BeOne Medicines director Margaret Dugan disposed American Depositary Shares to satisfy tax withholding on vested restricted share units. She sold 212 American Depositary Shares at an average price of $309.6017 per ADS in an open-market transaction tied to a mandatory tax provision in her RSU award agreement.
Each American Depositary Share represents 13 Ordinary Shares. After these transactions, she holds 54,184 Ordinary Shares directly and no American Depositary Shares, indicating she retained a substantial equity position while covering tax obligations from the RSU vesting.
BeOne Medicines Ltd. director Sanders Corazon (Corsee) D. reported a small tax-related share sale. On May 22, 2026, the director sold 212 American Depositary Shares at $309.5896 per ADS, with each ADS representing 13 Ordinary Shares. The sale was mandated under a tax withholding provision tied to the vesting of a restricted share unit award, rather than a discretionary market trade.
Following this transaction, the director holds 54,470 Ordinary Shares directly and no American Depositary Shares. The footnotes state that the restricted share units vest based on service on the board, with potential accelerated vesting upon a change in control or certain termination events.
BeOne Medicines Ltd. insiders linked to Baker Bros. entities reported small share sales tied to RSU vesting and tax withholding. On May 22, 2026, Michael Goller sold 2,743 ordinary shares at $23.8512 per share and Ranjeev Krishana sold 2,756 ordinary shares at $23.7905 per share. Footnotes explain these 5,499 ordinary shares, in the form of 423 American Depositary Shares (ADS), were sold in connection with the vesting of restricted stock units as mandatory tax-withholding transactions, not discretionary open-market selling. The positions are attributed to funds advised by Baker Bros. Advisors LP, which has voting and dispositive power, while Julian and Felix Baker and related entities disclaim beneficial ownership beyond their indirect pecuniary interest. After these transactions, the funds continue to hold large positions, including 8,068,411 ADS and 730,642 ADS reported as indirect holdings.
BeOne Medicines Ltd. director Shalini Sharp filed an amended Form 3 to correct her initial insider holdings. The amendment now reflects ownership of 9 American Depositary Shares, held directly. A footnote explains that each ADS represents 13 Ordinary Shares. This update does not report any new buy or sell transactions; it simply adds ADS that were omitted from the original Form 3 and subsequent Forms 4, leaving all other previously reported information unchanged.